HRP20120490T1 - Spojevi za inhibiciju napredovanja mitoze - Google Patents
Spojevi za inhibiciju napredovanja mitoze Download PDFInfo
- Publication number
- HRP20120490T1 HRP20120490T1 HRP20120490TT HRP20120490T HRP20120490T1 HR P20120490 T1 HRP20120490 T1 HR P20120490T1 HR P20120490T T HRP20120490T T HR P20120490TT HR P20120490 T HRP20120490 T HR P20120490T HR P20120490 T1 HRP20120490 T1 HR P20120490T1
- Authority
- HR
- Croatia
- Prior art keywords
- aliphatic
- group
- fluoroaliphatic
- compound according
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 230000008600 mitotic progression Effects 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 10
- 125000005843 halogen group Chemical group 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- -1 -OH Chemical group 0.000 claims 6
- 102000003989 Aurora kinases Human genes 0.000 claims 5
- 108090000433 Aurora kinases Proteins 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- SRFVRJILPIASPG-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2N(C=CC=2)C)=C1 SRFVRJILPIASPG-UHFFFAOYSA-N 0.000 claims 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 claims 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- AIUYVPGHBMKGAC-UHFFFAOYSA-M sodium;4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoate Chemical compound [Na+].C1=C(C([O-])=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 AIUYVPGHBMKGAC-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85934006P | 2006-11-16 | 2006-11-16 | |
| PCT/US2007/023948 WO2008063525A1 (fr) | 2006-11-16 | 2007-11-14 | Composés destinés à inhiber la progression mitotique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120490T1 true HRP20120490T1 (hr) | 2012-07-31 |
Family
ID=39315133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120490TT HRP20120490T1 (hr) | 2006-11-16 | 2012-06-12 | Spojevi za inhibiciju napredovanja mitoze |
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US8026246B2 (fr) |
| EP (4) | EP2086981B1 (fr) |
| JP (3) | JP5102839B2 (fr) |
| KR (2) | KR101342014B1 (fr) |
| CN (2) | CN101547924B (fr) |
| AR (1) | AR064246A1 (fr) |
| AT (1) | ATE556076T1 (fr) |
| AU (1) | AU2007322046B2 (fr) |
| BR (1) | BRPI0718803B8 (fr) |
| CA (1) | CA2669680C (fr) |
| CL (1) | CL2007003244A1 (fr) |
| CR (3) | CR10782A (fr) |
| CY (1) | CY1112828T1 (fr) |
| DK (2) | DK2086981T3 (fr) |
| EA (1) | EA015779B1 (fr) |
| ES (3) | ES2537451T3 (fr) |
| GE (1) | GEP20125459B (fr) |
| HK (4) | HK1134672A1 (fr) |
| HR (2) | HRP20120490T1 (fr) |
| IL (1) | IL198690A0 (fr) |
| MA (1) | MA30988B1 (fr) |
| MX (3) | MX348568B (fr) |
| MY (1) | MY153243A (fr) |
| NO (1) | NO343338B1 (fr) |
| NZ (3) | NZ577042A (fr) |
| PH (1) | PH12012502057A1 (fr) |
| PL (2) | PL2086981T3 (fr) |
| PT (2) | PT2497772E (fr) |
| RS (2) | RS53788B1 (fr) |
| SG (2) | SG176443A1 (fr) |
| SI (2) | SI2497772T1 (fr) |
| TW (1) | TWI401255B (fr) |
| UA (1) | UA94129C2 (fr) |
| WO (1) | WO2008063525A1 (fr) |
| ZA (1) | ZA200903279B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2540987T3 (es) | 2004-05-14 | 2015-07-15 | Millennium Pharmaceuticals, Inc. | Métodos para preparar inhibidores de la aurora cinasa |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| JP5684719B2 (ja) * | 2008-12-05 | 2015-03-18 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン |
| MX2011006725A (es) * | 2008-12-22 | 2011-09-15 | Millennium Pharm Inc | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| RU2012140021A (ru) * | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| ES2526671T3 (es) * | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| TW201316991A (zh) | 2011-06-03 | 2013-05-01 | Millennium Pharm Inc | Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合 |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103772391A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
| EP3076963A4 (fr) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de kinase aurora et d'anticorps anti-cd30 |
| JP2018502089A (ja) * | 2014-12-23 | 2018-01-25 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ |
| JP2018524292A (ja) | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼインヒビターと化学療法剤の投与 |
| WO2017044567A1 (fr) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Sulfonamides hétérocycliques tricycliques contraints en tant qu'agents anti-cancéreux |
| CA2997784A1 (fr) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Sulfonamides heterocycliques tricycliques contraints en tant qu'agents anti-cancereux |
| WO2017146253A1 (fr) | 2016-02-26 | 2017-08-31 | 公益財団法人がん研究会 | Procédé de criblage d'agent anticancéreux focalisé sur la fonction de hp1, et système d'évaluation |
| MX2018011102A (es) | 2016-03-15 | 2019-01-10 | Oryzon Genomics Sa | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. |
| JP6188986B1 (ja) * | 2017-03-23 | 2017-08-30 | 株式会社ノエビア | 時計遺伝子発現量調整剤及びエラスチン産生促進剤 |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| WO2020049208A1 (fr) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida |
| WO2021041532A1 (fr) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1 |
| WO2023196959A1 (fr) | 2022-04-07 | 2023-10-12 | Eli Lilly And Company | Procédé de fabrication d'un inhibiteur de kras g12c |
| WO2023196887A1 (fr) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a |
| US20240108618A1 (en) | 2022-06-30 | 2024-04-04 | Eli Lilly And Company | Kras g12c inhibitor dosing regimens |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| NL8000715A (nl) | 1979-02-07 | 1980-08-11 | Hoffmann La Roche | Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten. |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (fr) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6124281A (en) | 1996-03-08 | 2000-09-26 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
| WO1998028281A1 (fr) * | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| TW510902B (en) | 1997-09-29 | 2002-11-21 | Meiji Seika Kaisha | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| ATE403644T1 (de) | 1999-12-06 | 2008-08-15 | Ajinomoto Kk | Amidinophenylbrenztraubensäure-derivat |
| ATE326462T1 (de) | 2000-12-21 | 2006-06-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinase- inhibitoren |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) * | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| WO2003013545A1 (fr) | 2001-08-09 | 2003-02-20 | Actelion Pharmaceuticals Ltd | Heterocycles a fusion benzo utilises comme antagonistes vis-a-vis de l'endotheline |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| ES2540987T3 (es) | 2004-05-14 | 2015-07-15 | Millennium Pharmaceuticals, Inc. | Métodos para preparar inhibidores de la aurora cinasa |
| US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| WO2006070198A1 (fr) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora |
| DK1962830T3 (da) | 2005-12-23 | 2013-06-24 | Glaxosmithkline Llc | Azaindolhæmmere af aurorakinaser. |
| WO2008021038A2 (fr) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazépines et méthodes d'inhibition de la progression mitotique |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
-
2007
- 2007-11-09 CL CL200703244A patent/CL2007003244A1/es unknown
- 2007-11-14 PL PL07867449T patent/PL2086981T3/pl unknown
- 2007-11-14 ES ES12153134.7T patent/ES2537451T3/es active Active
- 2007-11-14 KR KR1020117022355A patent/KR101342014B1/ko active IP Right Grant
- 2007-11-14 CN CN2007800423837A patent/CN101547924B/zh active Active
- 2007-11-14 MX MX2012011396A patent/MX348568B/es unknown
- 2007-11-14 AU AU2007322046A patent/AU2007322046B2/en active Active
- 2007-11-14 SG SG2011080652A patent/SG176443A1/en unknown
- 2007-11-14 ES ES07867449T patent/ES2384123T3/es active Active
- 2007-11-14 JP JP2009537199A patent/JP5102839B2/ja active Active
- 2007-11-14 ES ES12153131.3T patent/ES2528793T3/es active Active
- 2007-11-14 SI SI200731591T patent/SI2497772T1/sl unknown
- 2007-11-14 CA CA2669680A patent/CA2669680C/fr active Active
- 2007-11-14 WO PCT/US2007/023948 patent/WO2008063525A1/fr active Application Filing
- 2007-11-14 SG SG10201503350TA patent/SG10201503350TA/en unknown
- 2007-11-14 EP EP07867449A patent/EP2086981B1/fr active Active
- 2007-11-14 MY MYPI20091846A patent/MY153243A/en unknown
- 2007-11-14 UA UAA200906211A patent/UA94129C2/ru unknown
- 2007-11-14 PT PT121531313T patent/PT2497772E/pt unknown
- 2007-11-14 EP EP12153131.3A patent/EP2497772B1/fr active Active
- 2007-11-14 AT AT07867449T patent/ATE556076T1/de active
- 2007-11-14 ZA ZA200903279A patent/ZA200903279B/xx unknown
- 2007-11-14 DK DK07867449.6T patent/DK2086981T3/da active
- 2007-11-14 US US11/985,277 patent/US8026246B2/en active Active
- 2007-11-14 SI SI200730975T patent/SI2086981T1/sl unknown
- 2007-11-14 DK DK12153131.3T patent/DK2497772T3/en active
- 2007-11-14 TW TW096143087A patent/TWI401255B/zh active
- 2007-11-14 GE GEAP200711309A patent/GEP20125459B/en unknown
- 2007-11-14 MX MX2009004670A patent/MX2009004670A/es active IP Right Grant
- 2007-11-14 BR BRPI0718803A patent/BRPI0718803B8/pt active IP Right Grant
- 2007-11-14 MX MX2012011398A patent/MX343391B/es unknown
- 2007-11-14 RS RS20150047A patent/RS53788B1/en unknown
- 2007-11-14 CN CN201310367332.9A patent/CN103483343B/zh active Active
- 2007-11-14 PL PL12153131T patent/PL2497772T3/pl unknown
- 2007-11-14 RS RS20120247A patent/RS52313B/en unknown
- 2007-11-14 NZ NZ577042A patent/NZ577042A/en unknown
- 2007-11-14 NZ NZ597252A patent/NZ597252A/xx unknown
- 2007-11-14 EP EP15155821.0A patent/EP2944639B1/fr active Active
- 2007-11-14 EP EP12153134.7A patent/EP2497773B1/fr active Active
- 2007-11-14 PT PT07867449T patent/PT2086981E/pt unknown
- 2007-11-14 EA EA200970486A patent/EA015779B1/ru unknown
- 2007-11-14 KR KR1020097012501A patent/KR101110458B1/ko active IP Right Grant
- 2007-11-14 NZ NZ611898A patent/NZ611898A/en not_active IP Right Cessation
- 2007-11-16 AR ARP070105104A patent/AR064246A1/es unknown
-
2009
- 2009-05-08 CR CR10782A patent/CR10782A/es unknown
- 2009-05-11 IL IL198690A patent/IL198690A0/en active IP Right Grant
- 2009-05-13 NO NO20091864A patent/NO343338B1/no unknown
- 2009-06-12 MA MA31985A patent/MA30988B1/fr unknown
-
2010
- 2010-02-11 HK HK10101590.0A patent/HK1134672A1/xx unknown
-
2011
- 2011-08-25 US US13/217,659 patent/US20110312942A1/en not_active Abandoned
- 2011-08-25 US US13/217,729 patent/US9988384B2/en active Active
- 2011-08-30 JP JP2011187930A patent/JP5452811B2/ja active Active
-
2012
- 2012-06-06 CY CY20121100518T patent/CY1112828T1/el unknown
- 2012-06-12 HR HRP20120490TT patent/HRP20120490T1/hr unknown
- 2012-10-12 PH PH12012502057A patent/PH12012502057A1/en unknown
-
2013
- 2013-03-08 HK HK13102944.8A patent/HK1175777A1/xx unknown
- 2013-03-11 HK HK13102986.7A patent/HK1175778A1/xx unknown
- 2013-11-15 JP JP2013236439A patent/JP2014055166A/ja active Pending
-
2014
- 2014-04-04 CR CR20140154A patent/CR20140154A/es unknown
- 2014-10-15 US US14/514,687 patent/US9765076B2/en active Active
- 2014-11-27 CR CR20140544A patent/CR20140544A/es unknown
-
2015
- 2015-01-13 HR HRP20150047TT patent/HRP20150047T1/hr unknown
-
2016
- 2016-05-17 HK HK16105677.1A patent/HK1217699A1/zh unknown
-
2018
- 2018-06-01 US US15/996,166 patent/US10836766B2/en active Active
-
2020
- 2020-11-16 US US17/099,266 patent/US11958855B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120490T1 (hr) | Spojevi za inhibiciju napredovanja mitoze | |
| CN101675053B (zh) | 磷酸肌醇3-激酶抑制剂化合物及使用方法 | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| ES2970074T3 (es) | Inhibidor de ATR y su aplicación | |
| JP2010510215A5 (fr) | ||
| ES2668834T3 (es) | Pirimidinas macrociclicas como inhibidores de proteína quinasas | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20120785T1 (hr) | Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| ATE361916T1 (de) | Pyrimidine verbindungen | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| CN102089312A (zh) | 作为蛋白酶体抑制剂的Salinosporamide衍生物 | |
| RU2341527C1 (ru) | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ | |
| EA201991025A1 (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина | |
| RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| EP2291376A2 (fr) | Naphtyridininones en tant qu inhibiteurs d aurora kinase | |
| SE0300091D0 (sv) | Novel compounds | |
| JP2014524449A5 (fr) | ||
| RS51320B (sr) | Derivati imidazohinolina kao veznici a3 receptora adenozina | |
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет |